Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

Video

In Partnership With:

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

At the 13th Annual International Congress on the Future of Breast Cancer, O’Regan discussed novel insights into adjuvant therapy for HER2-positive breast cancer. O’Regan says she reviewed how far we’ve come by using trastuzumab-based chemotherapy. O’Regan also noted that it appears that the addition of more novel therapies will not improve outcomes in this population of patients.

Physicians need to discuss if their patients can receive less trastuzumab if tumors are small and if molecular testing to determine which patients would benefit from trastuzumab is an option, O’Regan says. The idea of giving less or no chemotherapy is also being discussed for patients in this space. O’Regan says more research is needed.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute